Advertisement

Related Videos

Peter Clark, MA, MD, FRCP: A Payer Perspective

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Welcome and Introduction to Vi3C

David A. Hyman, MD, JD, on Inclusive Shared Savings

Advertisement

Advertisement




Aug
20
Today In Oncology
County-Level Medical Debt Linked to Advanced-Stage Cancers, Worse Survival Among Newly Diagnosed U.S. Adults
Mosunetuzumab With or Without Response-Adapted Therapy in Previously Untreated Indolent B-Cell Non-Hodgkin Lymphoma
Cleveland Clinic to Host Second Annual AI Summit for Health-Care Professionals
Digital Integrative Medicine Program Improves Overall Survival in Patients Undergoing Systemic Cancer Treatment
Adding a Radiopharmaceutical to Standard Therapy in mRCC Does Not Improve Skeletal Events
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo